/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2024-11-13 00:01:132024-11-13 00:06:00GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology
/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2024-01-23 04:00:212024-01-23 04:03:15GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease
/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2023-12-13 08:00:102024-01-18 15:15:26GenEdit Is a Phase I Winner of the NIH TARGETED Challenge
/wp-content/uploads/logo.png00Jennifer Cygan/wp-content/uploads/logo.pngJennifer Cygan2022-02-01 05:03:092022-02-01 05:15:50Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2021-09-23 04:00:052021-09-22 17:51:25GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2019-12-11 08:00:102024-01-23 18:42:18GenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery
